Sarepta delays Elevidys study readout while Emergent cuts 90 jobs

Sarepta Therapeutics told investors that the readout for its non‑ambulatory Elevidys trial will not be available by the end of the year as previously expected. The company indicated the delay during its recent earnings call, noting that only 12‑week data have been collected so far.

The postponement pushes the timeline for the study’s results further into the future, which may affect expectations for the gene‑therapy’s progress in treating Duchenne muscular dystrophy.

In separate news, Emergent BioSolutions announced it is reducing its workforce by 90 employees. The layoffs reflect a restructuring effort aimed at cutting costs amid broader market pressures.

Both developments underscore the challenges facing biotech firms as they navigate clinical timelines and operational efficiencies.